Patient-Led Drug Development for Rare Genetic Diseases Faces Ethical Scrutiny in Clinical Design and Regulatory Hurdles
Background
Among the more than 7,000 types of rare genetic diseases worldwide, the proportion of those with approved treatments remains around 5%. Due to small patient populations and a severe lack of baseline data on natural disease progression, large pharmaceutical companies have hesitated to conduct research due to profitability concerns relative to development costs. Patients and caregivers, desperate for treatment opportunities, have begun establishing research foundations or raising funds to participate in biotech startups. This is known as the Patient-Focused Drug Development (PFDD) model.
Patient advocacy groups are actively intervening in the entire process, from setting clinical endpoints to pre-meetings with regulatory agencies. Their dedication has acted as a powerful driver, accelerating pipeline discovery and lowering barriers to clinical entry. Conversely, complex ethical tensions, previously unseen, are emerging between academia, which must ensure scientific rigor; pharmaceutical companies, which pursue commercial profit; and regulatory agencies, which ultimately verify public health safety.
Key Findings
A recent analysis published in Nature Genetics identified three core recurring ethical conflict points in patient-led rare disease drug development projects. Researchers closely tracked clinical cases of gene therapies and small molecules that were funded or directly involved by patient groups over the past decade.
The first issue appears in clinical trial design and patient recruitment criteria. Families facing life-threatening situations for their children tend to prefer natural history controls or single-arm studies and strongly reject assignment to placebo-controlled groups. Frequent disputes over the fairness of subject selection have occurred, such as cases where patients from specific families that funded early Phase 1/2 trials with small participant numbers were given priority. This manifests as a direct clash between the safety standards of regulatory authorities, which require strict statistical power, and the desperation of patient families.
The second friction arises in the process of intellectual property rights and pricing after commercialization. Despite a significant portion of the initial research costs being covered by donations and crowdfunding, commercial pharmaceutical companies that licensed the technology for follow-up clinical trials have continued to charge exorbitant annual prices reaching hundreds of millions of won. As research achievements, for which patient groups assumed direct risks, are attributed to the exclusive monopoly rights of private enterprises, a contradiction has emerged wherein even the patient groups that participated in fundraising are unable to secure access to treatment.
Finally, governance issues regarding patient registry data were prominent. This is due to the absence of prior agreement on whether the ownership of genomic information and natural history data—core assets for clinical development—belongs to non-profit organizations, academic hospitals, or for-profit enterprises. Cases have been reported where patient data was provided exclusively to specific pharmaceutical companies, hindering the development of competing substances, or where patient group representatives were involved in the decision-making of Contract Research Organizations (CROs) without sufficient Conflict of Interest (COI) screening.
Implications and Outlook
While the advantage of the patient's voice accelerating development is clear, critics point out that the sustainability of therapeutics cannot be guaranteed if regulatory rigor and research ethics are sacrificed. It is problematic if desperation serves as a pretext for undermining scientific standards or justifying unfair resource allocation.
Experts suggest codifying specific governance guidelines at the time of initial contracts between academia, industry, and patient groups. There are strong calls to include public accessibility clauses in pipelines funded by public funds, specifying provisions for reasonable price negotiations or preferential supply rights after approval. It is also cited as an essential task to have an independent bioethics committee intervene from the clinical protocol design stage to verify the objectivity of subject selection criteria. As the patient-led model enters a mature stage, it is time to establish a normative framework characterized by fairness and transparency, moving beyond development driven by emotion.
Nature Genetics, Published online: 30 October 2026; doi:10.1038/s41588-026-02824-3Patient and family groups increasingly drive the development of drugs for rare diseases, from trial design to regulatory strategy. This model of patient-focused drug development can accelerate therapies for rare diseases but also generates recurring ethical tensions with academic, industry and regulatory partners that remain underdiscussed.
Biotech companies and clinical researchers, both domestically and internationally, must significantly overhaul their partnership structures with patient groups following this analysis. First, it is necessary to establish a tripartite consultative body comprising patient groups, researchers, and independent ethics experts prior to the initiation of clinical trials to standardize subject eligibility criteria and protocols for the use of placebo controls. In terms of data sovereignty, standard data use agreements should be prepared to share Patient Registry data through a public open platform rather than granting exclusive ownership to specific companies. In commercial licensing agreements, an operational model is expected to take root in the field by specifying benefit-sharing clauses that reflect patient co-payments when calculating drug prices, thereby preemptively preventing restricted access to therapeutics after drug approval.